{
    "nct_id": "NCT04640532",
    "official_title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.",
    "inclusion_criteria": "* Confirmed diagnosis of primary MF, post-PV MF, or post-ET MF, (WHO 2016)\n* ECOG â‰¤ 2\n* Cohort 1 and Cohort 2: R/R following JAK inhibitor treatment\n* Cohort 3: patients who are intolerant to JAK inhibitor treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with MDM2 inhibitors or p53-directed therapies\n* Prior treatment with a BCR-ABL, phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR), bromodomain and extraterminal domain (BET), histone deacetylase (HDAC), or spleen tyrosine kinase (Syk) inhibitor\n* Prior splenectomy\n* Splenic irradiation within 3 months prior to the first dose of study treatment\n* Clinically significant thrombosis within 3 months of screening\n* Grade 2 or higher QTc prolongation",
    "miscellaneous_criteria": ""
}